Haemolytic anaemia after cisplatin treatment.

Levi, John A.; Aroney, R. S.; Dalley, D.

doi:10.1136/bmj.282.6281.2003

Cited by 70 publications

(30 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20] showed that cisplatin causes significant effects on hematological parameters only during chronic treatment in humans and rats. Cisplatin-induced anemia is also a well-known side-effect [8][9] which occurs in 9-40% of patients [6] Our previous results showed that high, acute doses of cisplatin did not affect the RBC maturation in rats [8]The results of our study are in accordance with literature data, and show that chronic application of cisplatin induced depletion in RBC number and maturation. Animals also were treated with Alpha tocopherol which act as an antioxidant which can prevent the toxic effects of cisplatin.…”

Section: Discussionsupporting

confidence: 82%

Evaluation of the Ameliorative Properties of Alpha Tocopherol on Cisplatin Treated Adult Male Wistar Rats “Its Heamatologic Parameters and Repair Mechanism”

2017

International Journal of Research Studies in Microbiology and B

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 82%

Evaluation of the Ameliorative Properties of Alpha Tocopherol on Cisplatin Treated Adult Male Wistar Rats “Its Heamatologic Parameters and Repair Mechanism”

2017

International Journal of Research Studies in Microbiology and B

View full text Add to dashboard Cite

show abstract

“…Haemolytic anaemia has previously been reported with cisplatin (Levi et al, 1981) and carboplatin (Marani et al, 1996), as well as oxaliplatin. In contrast to the previous case report of oxaliplatinmediated haemolytic anaemia, our patient recovered with supportive treatment.…”

Section: Sirmentioning

confidence: 93%

“…He made a complete clinical recovery, with a platelet count of 122 000 µl Ϫ1 and a hemoglobin of 109 g l Ϫ1 2 weeks later while tapering off the steroids. In the month since this episode he has had continued disease stability, but he has not been re-challenged with oxaliplatin.Haemolytic anaemia has previously been reported with cisplatin (Levi et al, 1981) and carboplatin (Marani et al, 1996), as well as oxaliplatin. In contrast to the previous case report of oxaliplatinmediated haemolytic anaemia, our patient recovered with supportive treatment.…”

mentioning

confidence: 93%

See 1 more Smart Citation

Oxaliplatin-induced Evan’s syndrome

et al. 2001

View full text Add to dashboard Cite

Sir,Oxaliplatin is a third-generation platinum compound with activity in advanced colorectal cancer. It is available in several European countries, but remains investigational in North America. Its safety profile compares favourably with the other platinum-based agents, cisplatin and carboplatin, and consists mostly of peripheral neuropathy and mild thrombocytopenia. However, there has been one previous report in the literature of fatal haemolytic anaemia caused by oxaliplatin (Desrame et al, 1999). Here we report immune-mediated thrombocytopenia and concurrent haemolytic anaemia (Evan's syndrome) that developed during oxaliplatin infusion.In November of 1999, a 56-year-old man with a 2-year history of colon cancer metastatic to liver and lung, who had progressed on first-line 5-FU and leucovorin as well as second-line irinotecan, was enrolled on a Phase II study at the Dana-Farber Cancer Institute. Treatment consisted of oxaliplatin 85 mg/m 2 by bolus infusion over 2 hours, followed by 500 mg/m 2 of leucovorin also infused over 2 hours, 5-FU 400 mg/m 2 by rapid venous infusion, and then 5-FU 2400 mg/m 2 by continuous infusion with a portable pump over 46 hours. Treatment was repeated every 2 weeks. The patient had stable disease on this regimen between November 1999 and July 2000.In July, the patient came for a routine treatment with a platelet count of 99 000 µl -1 immediately prior to infusion. During the leucovorin infusion, approximately 5 hours after the baseline bloodwork was drawn and the oxaliplatin infusion initiated, he began feeling unwell and his gums began to bleed. He subsequently developed purpura on his oral mucosa and eyelids, haematuria and haematochezia. A repeat platelet count was 6000 µl -1 .He remained haemodynamically stable throughout, and initial haemoglobin and INR were normal. He was admitted to hospital for platelet transfusion and supportive care, but quickly also developed anaemia with a drop in his haemoglobin from 108 to 78 g l -1. Peripheral smear confirmed the decreased platelets, with a left shift in red cell morphology. There was anisocytosis and polychromasia, with a high RDW of 17.3 and increased reticulocytes at 4.7%. Bilirubin rose to 4.4 mg dl -1 , with only 1.4 mg dl -1 being direct, and the LDH increased to 2148 U l -1. Laboratory testing indicated a warm antibody, with a positive direct Coomb's test with polyspecific IgG. There was no anti-C3 antibody, and the eluate reacted with all cells. His INR also rose transiently to 2.4. Clotting factor levels and fibrinogen were normal, although Fibrin Split Products were elevated at 8 µg ml -1 . Screening for heparininduced thrombocytopenia and thrombosis (HITT) was negative.The patient was treated with prednisone 75 mg orally per day, with stabilization of his blood indices over the course of 3 days after receiving a total of 4 units of single donor platelets, 3 units of packed red blood cells, and 4 units of fresh frozen plasma. He made a complete clinical recovery, with a platelet count of 122 000 µl Ϫ1 and a hemoglobin of...

show abstract

“…Research findings have established that haemolytic anaemia can be developed after several courses of cisplatin which was suggested to be due to the reaction of an antibody with a cisplatin-red-cell membrane [12]. Thus, anaemia has been stated as a common side effect of cisplatin, especially after repeated infusions; the primary mechanism is a myelosuppression caused by cisplatin's interference with iron metabolism, resulting in a lower count of red cell precursors [13].…”

Section: Discussionmentioning

confidence: 99%

Hematological dynamics following the co-administration of Resveratrol and Cisplatin in Sprague–Dawley rats.

Okafor

Nweke²,

Nnamah

2018

J CLIN MED KAZ

View full text Add to dashboard Cite

Background: Cisplatin, a platinum-based chemotherapy agent, is used in the effective treatment of a wide range of malignant cancers. Resveratrol, a polyphenolic plant-derived compound, has been shown to have several biological effects including protecting the body against several forms of damages.Objective: This study assessed the effects of cisplatin and supplementation with resveratrol on some hematological parameters in Sprague-Dawley rats.Material and Methods: Forty-five adult female Sprague-Dawley rats, grouped into 9, were used for this experimental study. Group 1 served as the control group and received distilled water only. Groups 2 and 9 received Cisplatin only while groups 3, 4, and 5 received different doses of Resveratrol after a single dose of Cisplatin. Groups 6, 7, and 8 received Resveratrol before Cisplatin.Results: At the end of administration, blood samples were collected and different hematological parameters were accessed. Groups 2 and 5 showed a significantly higher Total WBC when compared to the control group (p<0.05). Group 7 showed a significantly higher (p<0.05) neutrophil count compared to both the control group and group 2, but a significant decrease in the lymphocyte count compared to the same groups (p<0.05). Groups 6 and 7 showed a significant reduction in monocyte when compared to the control group (p<0.05). There was no significant difference in the eosinophil count of all treatment groups when compared to the control group and cisplatin groups (p<0.05). Basophil increased significantly in group 7 when compared to the control group and group 2 (p<0.05). More so, a significant decrease in the Haemoglobin (Hb), Packed cell volume (PCV) and Mean corpuscular volume (MCV) level were observed when compared to group 9 (p<0.05).Conclusion: This study showed that cisplatin-induced alteration in some hematological parameters is reversible by treatment with resveratrol. More so, resveratrol supplementation should be incorporated as part of dietary nutrients for patients on cisplatin during chemotherapy. ТҰЖЫРЫМДАМА Кіріспе: Цисплатин -бұл түрлі қатерлі ісіктерді тиімді емдеуде пайдаланылатын химиотерапевтикалық препараты құрайтын пла-тин. Ресвератрол, шығуы өсімдік түрінен болатын полифенольді байланысудың зақымдалудың кейбір формаларынан организмді қорғауды қосқанда, бірнеше биологиялық әсері бар екендігі дәлелденді.Мақсаты: Осы зерттеуде Спрег-Доули егеуқұйрықтарындағы кейбір гематологиялық параметрлерге ресвератролдың қоспалары және цисплатиннің әсері бағаланды.Материалдар мен әдістер: Осы зерттеуде 9 топқа бөлінген қырық бес ересек Спрег-Доули егеуқұйрықтары қолданылды. 1-топ бақылау тобы болды және дистилденген суды ғана қабылдады. 2-ші және 9-шы топтар тек қана цисплатин қабылдады, сол уақытта 3, 4-ші Цель: В данном исследовании оценивались эффекты цисплатина и добавки ресвератрола на некоторые гематологические параметры у крыс Спрег-Доули.Материалы и методы: В данном исследовании было использовано сорок пять взрослых крыс Спрег-Доули, разделенных на 9 групп. Группа 1 стала кон...

show abstract

Haemolytic anaemia after cisplatin treatment.

Cited by 70 publications

References 4 publications

Evaluation of the Ameliorative Properties of Alpha Tocopherol on Cisplatin Treated Adult Male Wistar Rats “Its Heamatologic Parameters and Repair Mechanism”

Evaluation of the Ameliorative Properties of Alpha Tocopherol on Cisplatin Treated Adult Male Wistar Rats “Its Heamatologic Parameters and Repair Mechanism”

Oxaliplatin-induced Evan’s syndrome

Hematological dynamics following the co-administration of Resveratrol and Cisplatin in Sprague–Dawley rats.

Contact Info

Product

Resources

About